• About us
• Contact

Advertisement

Organisation › Details

Nextech Invest Ltd. (CH)

Nextech is a global, cancer therapeutics-focused venture capital firm headquartered in Zurich, Switzerland. Nextech focusses almost exclusively on oncology therapeutics, and on helping to drive value creation for their portfolio companies. Nextech invests in the most promising drug discovery companies with the potential to create multiple medicines. Nextech’s portfolio is focused throughout the US and Europe with investments from company inceptions to crossover rounds. *

 

	Start	2011-04-28 renamed before
	Group	Nextech (Group)
	Predecessor	Nextech Venture L.P.
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Scheidegger, Alfred (Nextech Invest 201104 CEO + Founding Partner)
	Person 2	Schröder, Thilo (Nextech Invest 201607 Partner)
	Region	Zürich ZH
	Country	Switzerland
	Street	35 Scheuchzerstr.
	City	8006 Zürich ZH
	Tel	+41-44-366-6611
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«: ITM Isotope Technologies Munich SE. (6/5/23). "Press Release: ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities". Garching.
		Record changed: 2024-12-29

Advertisement

More documents for Nextech (Group)

• [1] Exo Therapeutics, Inc.. (10/5/21). "Press Release: Exo Therapeutics Raises $78 Million Series B Financing". Cambridge, MA....
• [2] Hexagon Bio, Inc.. (9/22/21). "Press Release: Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes". Menlo Park, CA....
• [3] Biognosys AG. (5/19/21). "Press Release: Biognosys Announces the Appointment of Kristina Beeler as Chief Business Officer". Schlieren....
• [4] Boundless Bio, Inc.. (4/28/21). "Press Release: Boundless Bio Raises Oversubscribed $105 Million Series B Financing to Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal DNA (ecDNA)". San Diego, CA....
• [5] Moma Therapeutics, Inc.. (4/15/20). "Press Release: Moma Therapeutics – Drugging the Molecular Machines that Underlie Human Disease"....
• [6] Vividion Therapeutics, Inc.. (4/30/19). "Press Release: Vividion Therapeutics Announces Oversubscribed $82 Million Series B Financing". San Diego, CA....
• [7] Arrakis Therapeutics, Inc.. (4/18/19). "Press Release: Arrakis Therapeutics Announces $75 Million Series B Financing To Advance a New Class of Small-Molecule Medicines Targeting RNA". Waltham, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.